New therapy helps chinese cancer patients find purpose amid pain

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Phases 1 and 2: Interview Inclusion Criteria (per self-report): * Non-US born; * Of Chinese descent; * Age 21 years through 80 years; * Language spoken: Mandarin and/or English * Diagnosis of Stage IV cancer (any type). Phase 3: * Stage III or IV cancer (per self-report or on the MSKCC EMR). If traditional staging does not apply (i.e. for leukemia), we can allow patient deemed by provider to have poor prognosis/roughly equivalent to Stage III or IV to be referred. * Age 18 or older * Of Chinese descent * Mandarin-speaking * Have an estimated life expectancy of at least 6 months (per self-report or on the MSKCC EMR) * Resides in New York State or New Jersey Phase 4: * Stage III or IV cancer (per self-report or on the MSKCC EMR). If traditional staging does not apply (i.e. for leukemia), we can allow patient deemed by provider to have poor prognosis/roughly equivalent to Stage III or IV to be referred. * Age 18 or older * Of Chinese descent * Mandarin-speaking * Have an estimated life expectancy of at least 6 months (per referring physician assessment or on the MSKCC EMR) * Resides in New York State or New Jersey Exclusion Criteria: Phases 1 and 2: * Presence of cognitive impairment disorder (e.g., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection. The Chinese version of the Mini Mental State Examination (MMSE) (46) will be used as a cognitive screening tool. Patients with MMSE scores below 20 will be excluded. For English speaking patients we will use the English version of the MMSE. * Has a household member who has already participated (or agreed to participate). Phase 3: * Previous participation in Phases 1 or 2 of the study * Unable/unwilling to use or no access to a telehealth platform (i.e., telephone or videoconference) * For participants who express interest in RSMI, unable/unwilling to use Zoom videoconferencing platform * Unable or unwilling to commit to up to 16 weeks to complete 6-session intervention and follow-up assessments * Major psychiatric illness or cognitive impairment that in the judgment of study investigators or study staff would preclude study participation * Patients diagnosed with primary brain tumors (per self-report or on the MSKCC EMR), as they may have difficulty completing the intervention and answering questionnaires * Undergoing hematopoietic stem cell transplantation (HSCT) (per self-report or on the MSKCC EMR) * Currently in psychotherapeutic treatment (patients being treated with psychotropic medications will not be excluded, as long as they are not in psychotherapy; per self report) Phase 4: * Previous participation in Phases 1, 2, or 3 of the study * Unable/unwilling to use or no access to the Zoom videoconferencing platform (required for RSMI) * Unable or unwilling to commit to up to 16 weeks to complete 6-session intervention and follow-up assessments * Major psychiatric illness or cognitive impairment that in the judgment of study investigators or study staff would preclude study participation * Patients diagnosed with primary brain tumors (per self-report or on the MSKCC EMR), as they may have difficulty completing the intervention and answering questionnaires * Undergoing hematopoietic stem cell transplantation (HSCT) (per self-report or on the MSKCC EMR) * Currently in psychotherapeutic treatment (patients being treated with psychotropic medications will not be excluded, as long as they are not in psychotherapy; per self report)